You are here

Fact Sheet on Dovato 2-Drug HIV Regimen

Wednesday, May 15, 2019


A fact sheet on Dovato (Dolutegravir/Lamivudine or DTG/3TC), the first two-drug regimen for initial HIV treatment, has been released by AIDSinfo, with links to the patient version and FDA label. Nearly 60 HIV medicines have been approved by FDA since 1987 (see chart below). 

Dovato received an A1 rating in the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, with the comment: "Emerging data support the use of two-drug regimens, such as dolutegravir (DTG) plus 3TC, when ABC, TDF, and TAF cannot be used or are not optimal." The Dovato fact sheet and Guidelines outline additional considerations and cautionary notes on use of Dovato. 

Dovato was summarized in a recent AETC ShareSpot, FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine, which summarized clinical data supporting its approval, qualifications on its use, with the explanation that Dovato's approval is "intended only for adults who have never received ART and whose HIV has no resistance to either of the two components."

See AIDSInfo's searchable database of HIV-related drugs.

Total views: 139